A total blood volume or more transfused during pregnancy or after childbirth: Individual patient data from six international population-based observational studies.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
11
2020
accepted:
20
12
2020
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
8
5
2021
Statut:
epublish
Résumé
This study aimed to compare incidence, management and outcomes of women transfused their blood volume or more within 24 hours during pregnancy or following childbirth. Combined analysis of individual patient data, prospectively collected in six international population-based studies (France, United Kingdom, Italy, Australia, the Netherlands and Denmark). Massive transfusion in major obstetric haemorrhage was defined as transfusion of eight or more units of red blood cells within 24 hours in a pregnant or postpartum woman. Causes, management and outcomes of women with massive transfusion were compared across countries using descriptive statistics. The incidence of massive transfusion was approximately 21 women per 100,000 maternities for the United Kingdom, Australia and Italy; by contrast Denmark, the Netherlands and France had incidences of 82, 66 and 69 per 100,000 maternities, respectively. There was large variation in obstetric and haematological management across countries. Fibrinogen products were used in 86% of women in Australia, while the Netherlands and Italy reported lower use at 35-37% of women. Tranexamic acid was used in 75% of women in the Netherlands, but in less than half of women in the UK, Australia and Italy. In all countries, women received large quantities of colloid/crystalloid fluids during resuscitation (>3·5 litres). There was large variation in the use of compression sutures, embolisation and hysterectomy across countries. There was no difference in maternal mortality; however, variable proportions of women had cardiac arrests, renal failure and thrombotic events from 0-16%. There was considerable variation in the incidence of massive transfusion associated with major obstetric haemorrhage across six high-income countries. There were also large disparities in both transfusion and obstetric management between these countries. There is a requirement for detailed evaluation of evidence underlying current guidance. Furthermore, cross-country comparison may empower countries to reference their clinical care against that of other countries.
Sections du résumé
BACKGROUND
This study aimed to compare incidence, management and outcomes of women transfused their blood volume or more within 24 hours during pregnancy or following childbirth.
METHODS
Combined analysis of individual patient data, prospectively collected in six international population-based studies (France, United Kingdom, Italy, Australia, the Netherlands and Denmark). Massive transfusion in major obstetric haemorrhage was defined as transfusion of eight or more units of red blood cells within 24 hours in a pregnant or postpartum woman. Causes, management and outcomes of women with massive transfusion were compared across countries using descriptive statistics.
FINDINGS
The incidence of massive transfusion was approximately 21 women per 100,000 maternities for the United Kingdom, Australia and Italy; by contrast Denmark, the Netherlands and France had incidences of 82, 66 and 69 per 100,000 maternities, respectively. There was large variation in obstetric and haematological management across countries. Fibrinogen products were used in 86% of women in Australia, while the Netherlands and Italy reported lower use at 35-37% of women. Tranexamic acid was used in 75% of women in the Netherlands, but in less than half of women in the UK, Australia and Italy. In all countries, women received large quantities of colloid/crystalloid fluids during resuscitation (>3·5 litres). There was large variation in the use of compression sutures, embolisation and hysterectomy across countries. There was no difference in maternal mortality; however, variable proportions of women had cardiac arrests, renal failure and thrombotic events from 0-16%.
INTERPRETATION
There was considerable variation in the incidence of massive transfusion associated with major obstetric haemorrhage across six high-income countries. There were also large disparities in both transfusion and obstetric management between these countries. There is a requirement for detailed evaluation of evidence underlying current guidance. Furthermore, cross-country comparison may empower countries to reference their clinical care against that of other countries.
Identifiants
pubmed: 33481835
doi: 10.1371/journal.pone.0244933
pii: PONE-D-20-34935
pmc: PMC7822517
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244933Subventions
Organisme : Medical Research Council
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Obstet Gynecol. 2015 Jul;213(1):76.e1-76.e10
pubmed: 25731692
Int J Obstet Anesth. 2020 May;42:11-19
pubmed: 31402309
Acta Obstet Gynecol Scand. 2018 Nov;97(11):1317-1324
pubmed: 29956300
Bull World Health Organ. 2001;79(4):373-4
pubmed: 11357217
Br J Haematol. 2015 Sep;170(6):788-803
pubmed: 26147359
BJOG. 2005 Mar;112(3):263-5
pubmed: 15713136
Obstet Gynecol. 2014 Jan;123(1):126-133
pubmed: 24463672
JAMA. 2019 Oct 21;:1-11
pubmed: 31634905
Am J Obstet Gynecol. 2010 Feb;202(2):150.e1-7
pubmed: 19922900
Eur J Obstet Gynecol Reprod Biol. 2016 Mar;198:12-21
pubmed: 26773243
Crit Care Med. 2013 Aug;41(8):1844-52
pubmed: 23648568
Eur J Obstet Gynecol Reprod Biol. 2019 Apr;235:49-56
pubmed: 30784827
Gynecol Obstet Fertil Senol. 2017 Dec;45(12S):S8-S21
pubmed: 29113879
BJOG. 2016 Dec;123(13):2164-2170
pubmed: 26694742
Crit Care. 2011;15(2):R117
pubmed: 21496253
Aust N Z J Obstet Gynaecol. 2013 Apr;53(2):152-7
pubmed: 23216366
Br J Anaesth. 2015 Apr;114(4):623-33
pubmed: 25586727
Lancet. 2017 May 27;389(10084):2105-2116
pubmed: 28456509
PLoS One. 2013 Jun 24;8(6):e66882
pubmed: 23826165
Gynecol Obstet Fertil. 2005 Apr;33(4):268-74
pubmed: 15894217
J Thromb Haemost. 2018 Jun 8;:
pubmed: 29883040
Cochrane Database Syst Rev. 2012 Mar 14;(3):CD005011
pubmed: 22419303
Anesth Analg. 2017 Jan;124(1):216-232
pubmed: 27557476
Anaesth Crit Care Pain Med. 2019 Aug;38(4):363-369
pubmed: 30583117
BMC Pregnancy Childbirth. 2017 Jun 19;17(1):197
pubmed: 28629440
Br J Haematol. 2016 Feb;172(4):616-24
pubmed: 26683982
Anesth Analg. 2012 Feb;114(2):261-74
pubmed: 21965371
BMC Pregnancy Childbirth. 2009 Nov 27;9:55
pubmed: 19943928
BJOG. 2016 Mar;123(4):598-605
pubmed: 26113356
Br J Anaesth. 2014 Dec;113(6):922-34
pubmed: 24972790
Crit Care Med. 2018 Oct;46(10):e1002-e1009
pubmed: 30059363
Arch Gynecol Obstet. 2013 Mar;287(3):463-8
pubmed: 23064441
CMAJ. 2019 Apr 1;191(13):E352-E360
pubmed: 30936165